Radioembolization in the treatment of unresectable liver tumors: Experience across a range of primary cancers

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 2, 2012, Pages 167-177

  Coldwell, Douglas ^a   Sangro, Bruno ^e   Salem, Riad ^b   Wasan, Harpreet ^f   Kennedy, Andrew ^c,d  

^a UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Wake Radiology Oncology   (United States)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

Breast; Cholangiocarcinoma; Melanoma; SIR.T.; Yttrium 90

Indexed keywords

AMINOTRANSFERASE; ANALGESIC AGENT; BILIRUBIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GLASS MICROSPHERE; IRINOTECAN; MICROSPHERE; NAVELBINE; RESIN MICROSPHERE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; YTTRIUM 90; GLASS; RESIN; YTTRIUM;

ABDOMINAL DISCOMFORT; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTIFICIAL EMBOLISM; ASCITES; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BILIRUBIN BLOOD LEVEL; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLECYSTITIS; CLINICAL EFFECTIVENESS; COLORECTAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DUODENUM ULCER; FATIGUE; GASTRODUODENAL ULCER; HEMIHEPATECTOMY; HUMAN; LIVER CELL CARCINOMA; LIVER HYPERTROPHY; LIVER METASTASIS; LIVER NECROSIS; LIVER TOXICITY; LIVER TUMOR; LOBECTOMY; LUNG CANCER; LYMPH NODE METASTASIS; MICROWAVE THERAPY; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; RADIATION SICKNESS; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH ULCER; THORAX PAIN; TREATMENT RESPONSE; TUMOR ABLATION; UPPER ABDOMINAL PAIN; UVEA MELANOMA; BILE DUCT TUMOR; BREAST TUMOR; INTRAHEPATIC BILE DUCT; LIVER RESECTION; LUNG TUMOR; MELANOMA; METASTASIS; METHODOLOGY; PATHOLOGY; TREATMENT OUTCOME; UVEA TUMOR;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; GLASS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MELANOMA; MICROSPHERES; RESINS, SYNTHETIC; TREATMENT OUTCOME; UVEAL NEOPLASMS; YTTRIUM RADIOISOTOPES;

EID: 84860645692     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181f47923     Document Type: Review

References (64)

1. Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of 90Y microspheres in man: Review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60: 1552-1563. (Pubitemid 39601873)
2. Dikomey E, Borgmann K, Peacock J, et al. Why recent studies relating normal tissue response to individual radiosensitivity might have failed and how new studies should be performed. Int J Radiat Oncol Biol Phys. 2003;56:1194-2000.
3. Nemato T, Dao TL. Significance of liver metastases in women with disseminated breast cancer undergoing endocrine ablative surgery. Cancer. 1966;19:421-427.
4. Viadana E, Bross ID, Pickren JW. An autopsy study of some routes of dissemination of cancer of the breast. Br J Cancer. 1973;27:336-340.
5. Er O, Frye DK, Kau SW, et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J. 2008;14:62-68.
6. Pentheroudakis G, Fountzilas G, Bafaloukos D, et al. Metastatic breast cancer with liver metastases: A registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat. 2006;97:237-244. (Pubitemid 43945754)
7. Vlastos G, Smith DL, Singletary SE, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol. 2004;11:869-874.
8. Atalay G, Biganzoli L, Renard F, et al; EORTC Breast Cancer and Early Clinical Studies Groups. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: A retrospective analysis of two prospective, randomized metastatic breast cancer trials. Eur J Cancer. 2003;39:2439-2449. (Pubitemid 37340158)
9. Eichbaum MH, Kaltwasser M, Bruckner T, et al. Prognostic factors for patients with liver metastases from breast cancer. Breast Cancer Res Treat. 2006;96:53-62.
10. Elias D, Maisonnette F, Druet-Cabanac M, et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg. 2003;185:158-164. (Pubitemid 36143907)
11. Lawes D, Chopada A, Gillams A, et al. Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastasis from breast cancer. Ann R Coll Surg. Engl. 2006;88:639-642. (Pubitemid 44768571)
12. Gunabushanam G, Sharma S, Thulkar S, et al. Radiofrequency ablation of liver metastases from breast cancer: Results in 14 patients. J Vasc Interv Radiol. 2007;18:67-72. (Pubitemid 46616669)
13. Amersi FF, McElrath-Garza A, Ahmad A, et al. Long-term survival after radiofrequency ablation of complex unresectable liver tumors. Arch Surg. 2006;141:581-587.
14. Liang P, Dong BW, Yu XL, et al. Evaluation of long-term therapeutic effects of ultrasound-guided percutaneous microwave ablation of liver metastases. Zhonghua Yi Xue Za Zhi. 2006;86: 806-810.
15. Abe H, Kurumi Y, Naka S, et al. Open-configuration MR-guided microwave thermocoagulation therapy for metastatic liver tumors from breast cancer. Breast Cancer. 2005;12:26-31.
16. Seifert JK, Junginger T. Cryotherapy for liver tumors: Current status, perspectives, clinical results, and review of literature. Technol Cancer Res Treat. 2004;3:151-163. (Pubitemid 38544262)
17. Giroux MF, Baum RA, Soulen MC. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol. 2004;15: 289-291. (Pubitemid 38316452)
18. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys. 2007;69: 800-804. (Pubitemid 47418394)
19. Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol. 2008;19:683-690.
20. Bangash AK, Atassi B, Kaklamani V, et al. 90Y radioembolization of metastatic breast cancer to the liver: Toxicity, imaging response, survival. J Vasc Interv Radiol. 2007;18:621-628. (Pubitemid 46661173)
21. Hoffmann RT, Jakobs TF, Kubisch C, et al. Radiofrequency ablation after selective internal radiation therapy with yttrium-90 microspheres in metastatic liver disease: Is it feasible? Eur J Radiol. 2009 [Epub ahead of print].
22. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123:1639-1643. (Pubitemid 41785095)
23. Kennedy A, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest. 2009;27:682-690.
24. Murthy R, Mutha P, Lee JH, et al. Yttrium-90-labeled microsphere radioembolotherapy of liver-dominant metastases from thoracic malignancies. J Vasc Interv Radiol. 2008;19:299-300.
25. Gonsalves CF, Eschelman DJ, Sullivan KL, et al. Selective internal radiation therapy (SIRT) as salvage therapy for uveal melanoma (UM) hepatic metastases. Presented as a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, J Clin Oncol. 2009;27(May 20 Suppl):477s Abs. 9066.
26. Dhanasekaran R, Khanna V, Lawson D, et al. Survival benefits of yttrium-90 radioembolization (SIR-Spheres) for hepatic metastasis from melanoma: Preliminary study. Presented at the Society of Interventional Radiology (SIR) 34th Annual Scientific Meeting, J Vasc Interv Radiol. 2009;26(2S):S65 Abs. 167.
27. Khan SA, Davidson BR, Goldin R, et al. UK guidelines for the diagnosis and treatment of cholangiocarcinoma. Gut. 2002;51 (suppl 6):1-9.
28. Coldwell DM. Treatment of unresectable nodular cholangiocarcinoma with yttrium-90 microspheres. Presented as a poster at the World Congress on Gastrointestinal Cancer. Ann Oncol. 2006;17(suppl 6):vi56 Abs P-102.
29. Saxena A, Bester L, Chua TC, et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: A preliminary assessment of this novel treatment option. Ann Surg Oncol. 2009 ePub 30 Oct 2009 DOI: 10.1245/s10434-009-0777-x.
30. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: Results from a pilot study. Cancer. 2008;113:2119-2128.
31. Whitney R, Tatum C, Hahl M, et al. Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. J Surg Res. 2009 ePub doi:10.1016/j.jss.2009.05.021.
32. Johnson DW, Mori KH, O'Laughlin SR, et al. Safety and efficacy of yttrium-90 labeled microsphere radiation treatment for hepatic metastases. Northeast Florida Med. 2009;60:37-41.
33. Stuart JE, Tan B, Myerson RJ, et al. Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: Initial outcomes. J Vasc Interv Radiol. 2008;19:1427-1433.
34. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: Radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology. 2008;247: 507-515.
35. Rowe B, Weiner R, Foster J, et al. 90Yttrium microspheres for nonresectable liver cancer: The university of Connecticut health center experience. Conn Med. 2007;71:523-528.
36. Szyszko T, Al-Nahhas A, Canelo R, et al. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: Value of FDG PET versus computed tomography. Nucl Med Commun. 2007;28:15-20. (Pubitemid 44949683)
37. Tehranipour N, Al-Nahhas A, Canelo R, et al. Concordant F-18 FDG PET and Y-90 Bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: Confirmation with histopathology. Clin Nucl Med. 2007;32:371-374. (Pubitemid 46659171)
38. Jiao LR, Szyszko T, Al-Nahhas A, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol. 2007;33: 597-602. (Pubitemid 46746540)
39. Khodjibekova M, Szyszko T, Singh A, et al. Treatment of primary and secondary liver tumours with selective internal radiation therapy. J Exp Clin Cancer Res. 2007;26:561-570. (Pubitemid 351157875)
40. Jakobs TF, Hoffmann RT, Poepperl G, et al. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90yttrium resin-microspheres. Eur Radiol. 2007;17:1320-1330. (Pubitemid 46691963)
41. Pöpperl G, Helmberger T, Münzing W, et al. Selective internal radiation therapy with SIR-spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm. 2005;20:200-208. (Pubitemid 40696103)
42. Jakobs TF, Hoffmann RT, Yu M, et al. Yttrium-90 (SIRSpheress) treatment for metastatic cancer to the liver: Midterm result. Presented at the World Conference on Interventional Oncology. 2006; Session L1.
43. Gulec SA, Mesoloras G, Dezarn WA, et al. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med. 2007;5:15.
44. Gulec SA, Mesoloras G, Wiarda H, et al. Resin microsphere selective internal radiation treatment in primary and metastatic liver cancer: Objective response and therapeutic ratio analysis. Presented as a poster at the 7th Americas Hepatopancreatobiliary Congress. HPB. 2007;9:53. Abstract 62.
45. Yu M, Lewandowski RJ, Wong CO, et al. Yttrium-90 (SIRSpheres) treatment for metastatic cancer to the liver: Midterm results. Presented at the Society of Interventional Radiology (SIR) 31st Annual Scientific Meeting 2006; Abstract 17.
46. Wong CY, Qing F, Savin M, et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol. 2005;16:1101-1106. (Pubitemid 41177123)
47. Lim L, Gibbs P, Yip D, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J. 2005;35:222-227. (Pubitemid 40529583)
48. Alonso-Burgos A, Iñarrairaegui M, Sangro B, et al. Radioembolisation of liver tumors: Determinants of antitumor effect using Y90-labeled resin microspheres. Presented as a poster at the Cardiovascular and Interventional Radiology in Europe (CIRSE) Annual Meeting, Cardiovasc Interven Radiol. 2008; Abstract P74.
49. Bilbao I, Martinez-Cuesta A, Alonso-Burgos A, et al. Liver radioembolization (RE) with Y90 loaded resin microspheres: Results in 93 patients in a single institution. Presented at the Cardiovascular and Interventional Radiology in Europe (CIRSE) Annual Meeting, Cardiovasc Interven Radiol. 2007; Abstract 1303.3.
50. Boán J, Martí-Climent J, Martínez-Cuesta A, et al. Selective internal radiation therapy of primary or metastatic hepatic tumors with yttrium-90 microspheres. Presented as a poster at the European Association of Nuclear Medicine (EANM) Conference 2005; Abstract 295.
51. Cianni R, Saltarelli A, Notarianni E, et al. Radioembolism (yttrium 90) of hepatic liver mets. Preliminary experience. Presented as a poster at the World Conference on Interventional Oncology. 2006; Abstract.
52. Bailey W, Little A, Lim L, et al. Ytrium-90 microsphere hepatic artery embolization in the treatment of nonresectable hepatic malignancy. Presented at the Australasian Radiology Conference, 2003. Australasian Radiol. 2004;48:A4-A5.
53. Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: Preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16: 1587-1596.
54. Gulec SA, Pennington K, Hall M, et al. Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: A novel approach to improving the safety of major hepatic resections. World J Surg Oncol. 2009;7:6.
55. Siddiqi NH, Devlin PM. Radiation lobectomy-a minimally invasive treatment model for liver cancer: Case report. J Vasc Interv Radiol. 2009;20:664-669.
56. Gaba RC, Bui JT, Knuttinen MG, et al. Re: Radiation lobectomy-a minimally invasive treatment model for liver cancer. J Vasc Interv Radiol. 2009;20:1394-1396.
57. Murthy R, Brown DB, Salem R, et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol. 2007;18:553-561. (Pubitemid 46566540)
58. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with 90Y microspheres: Angiographic and technical considerations. Cardiovasc Interv Radiol. 2007;30:571-592. (Pubitemid 350092259)
59. Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494-1500.
60. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the Radioembolization Brachytherapy Oncology Consortium (REBOC). Int J Radiat Oncol Biol Phys. 2007;68:13-23. (Pubitemid 46589861)
61. Van der Pool AE, Mendez Romero A, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97:377-382.
62. Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am J Clin Oncol. 2010;33:157-163.
63. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multiinstitutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572-1578.
64. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585-1591.